JP7434616B2 - プロドラッグおよびその使用 - Google Patents

プロドラッグおよびその使用 Download PDF

Info

Publication number
JP7434616B2
JP7434616B2 JP2023007479A JP2023007479A JP7434616B2 JP 7434616 B2 JP7434616 B2 JP 7434616B2 JP 2023007479 A JP2023007479 A JP 2023007479A JP 2023007479 A JP2023007479 A JP 2023007479A JP 7434616 B2 JP7434616 B2 JP 7434616B2
Authority
JP
Japan
Prior art keywords
amino
compound
chem
substituent
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023007479A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023106355A5 (https=
JP2023106355A (ja
Inventor
パトリック・ジェイムズ・ナー
ブライアン・パトリック・ファイナン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2023106355A publication Critical patent/JP2023106355A/ja
Publication of JP2023106355A5 publication Critical patent/JP2023106355A5/ja
Priority to JP2023203905A priority Critical patent/JP2024015148A/ja
Application granted granted Critical
Publication of JP7434616B2 publication Critical patent/JP7434616B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023007479A 2022-01-20 2023-01-20 プロドラッグおよびその使用 Active JP7434616B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023203905A JP2024015148A (ja) 2022-01-20 2023-12-01 プロドラッグおよびその使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263301311P 2022-01-20 2022-01-20
US63/301,311 2022-01-20
EP22154309 2022-01-31
EP22154309 2022-01-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023203905A Division JP2024015148A (ja) 2022-01-20 2023-12-01 プロドラッグおよびその使用

Publications (3)

Publication Number Publication Date
JP2023106355A JP2023106355A (ja) 2023-08-01
JP2023106355A5 JP2023106355A5 (https=) 2023-11-24
JP7434616B2 true JP7434616B2 (ja) 2024-02-20

Family

ID=85036152

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023007479A Active JP7434616B2 (ja) 2022-01-20 2023-01-20 プロドラッグおよびその使用
JP2023203905A Pending JP2024015148A (ja) 2022-01-20 2023-12-01 プロドラッグおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023203905A Pending JP2024015148A (ja) 2022-01-20 2023-12-01 プロドラッグおよびその使用

Country Status (7)

Country Link
US (2) US11840560B2 (https=)
EP (1) EP4466069A1 (https=)
JP (2) JP7434616B2 (https=)
KR (2) KR102704620B1 (https=)
AR (1) AR128315A1 (https=)
TW (1) TW202330584A (https=)
WO (1) WO2023139187A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202511291A (zh) 2023-09-11 2025-03-16 丹麥商諾佛 儂迪克股份有限公司 抗ｉｌ－６結構域之抗體
JP7755031B2 (ja) * 2023-11-30 2025-10-15 ノヴォ ノルディスク アー／エス Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬
WO2025252197A1 (zh) * 2024-06-07 2025-12-11 江苏恒瑞医药股份有限公司 药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015504431A (ja) 2011-11-17 2015-02-12 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
JP2022527803A (ja) 2019-04-11 2022-06-06 ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド マルチ受容体刺激剤及びその医療上の使用
JP2023534131A (ja) 2020-07-22 2023-08-08 ノヴォ ノルディスク アー／エス 経口送達に好適なｇｌｐ－１受容体およびｇｉｐ受容体共作動薬

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
DK2300035T3 (en) 2008-06-17 2015-11-16 Univ Indiana Res & Tech Corp Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
CN102325539A (zh) 2008-12-19 2012-01-18 印第安纳大学研究及科技有限公司 基于酰胺的胰高血糖素超家族肽前药
CN102300580A (zh) 2008-12-19 2011-12-28 印第安纳大学研究及科技有限公司 二肽连接的药剂
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
EP2512518A1 (en) 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
EP2588127A4 (en) 2010-06-24 2014-06-11 Univ Indiana Res & Tech Corp DIPEPTIDE-NETWORKED MEDICAL ACTIVE SUBSTANCES
RU2580317C2 (ru) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
SG191252A1 (en) 2010-12-22 2013-07-31 Marcadia Biotech Inc Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
WO2012167744A1 (en) 2011-06-10 2012-12-13 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
EP3542790B1 (en) 2012-03-22 2023-09-13 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
JP6228187B2 (ja) 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
HRP20180936T1 (hr) 2012-06-21 2018-12-14 Indiana University Research And Technology Corporation Analozi glukagona koji pokazuju aktivnost prema receptoru za gip
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
CN105324125A (zh) 2013-03-15 2016-02-10 印第安纳大学研究及科技有限公司 具有长效的前体药物
JP6672140B2 (ja) 2013-05-02 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１化合物の経口投薬
LT3004155T (lt) 2013-05-28 2021-12-27 Takeda Pharmaceutical Company Limited Peptidų junginys
HK1226084A1 (zh) 2013-08-16 2017-09-22 Medimmune Limited 用於治疗糖尿病的gip和glp-1受体双重激动剂
WO2015035419A1 (en) 2013-09-09 2015-03-12 Hoffmann-La Roche Inc. Dosages of gip/glp-1 co-agonist peptides for human administration
MX2016005556A (es) 2013-11-06 2016-07-15 Zealand Pharma As Compuestos agonistas duales de gip-glp-1 y procedimientos.
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
GB2528436A (en) 2014-07-15 2016-01-27 Lancaster Univ Business Entpr Ltd Treatment of neurological diseases
WO2016049174A1 (en) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Lipidated amide-based insulin prodrugs
WO2016077220A1 (en) 2014-11-10 2016-05-19 Mb2 Llc Gip/glp-1 co-agonist peptides for human administration
JP2018012644A (ja) 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物
JO3575B1 (ar) 2015-01-09 2020-07-05 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
US20170112897A1 (en) 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
WO2017204219A1 (ja) 2016-05-24 2017-11-30 武田薬品工業株式会社 ペプチド化合物
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
JOP20190211A1 (ar) 2017-03-31 2019-09-15 Takeda Pharmaceuticals Co ببتيد منشط لمستقبل gip
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
KR102379958B1 (ko) 2018-05-04 2022-04-01 노보 노르디스크 에이/에스 Gip 유도체 및 이의 용도
CN120754229A (zh) 2018-07-23 2025-10-10 伊莱利利公司 使用gip/glp1共激动剂用于治疗的方法
CN112469731B (zh) 2018-07-23 2024-11-29 伊莱利利公司 Gip/glp1共激动剂化合物
EP3826662B9 (en) 2018-07-23 2025-02-19 Eli Lilly and Company Method of using a gip/glp1 co-agonist for diabetes
CN110642935A (zh) 2019-09-25 2020-01-03 成都奥达生物科技有限公司 一种替瑞帕肽类似物
CN110684082B (zh) 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015504431A (ja) 2011-11-17 2015-02-12 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
JP2022527803A (ja) 2019-04-11 2022-06-06 ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド マルチ受容体刺激剤及びその医療上の使用
JP2023534131A (ja) 2020-07-22 2023-08-08 ノヴォ ノルディスク アー／エス 経口送達に好適なｇｌｐ－１受容体およびｇｉｐ受容体共作動薬

Also Published As

Publication number Publication date
US11840560B2 (en) 2023-12-12
WO2023139187A1 (en) 2023-07-27
EP4466069A1 (en) 2024-11-27
TW202330584A (zh) 2023-08-01
KR20230159805A (ko) 2023-11-22
KR102704620B1 (ko) 2024-09-12
US20230227521A1 (en) 2023-07-20
AR128315A1 (es) 2024-04-17
JP2024015148A (ja) 2024-02-01
US20240083965A1 (en) 2024-03-14
KR20230112568A (ko) 2023-07-27
JP2023106355A (ja) 2023-08-01

Similar Documents

Publication Publication Date Title
JP7581385B2 (ja) 経口送達に好適なｇｌｐ－１受容体およびｇｉｐ受容体共作動薬
US9029325B2 (en) Amylin analogues and pharmaceutical compositions thereof
JP7484018B2 (ja) Ｇｌｐ－１プロドラッグおよびその使用
JP7434616B2 (ja) プロドラッグおよびその使用
US20230346961A1 (en) Glp-1 and gip receptor co-agonists
JP2025517672A (ja) プロドラッグおよびその使用
CA3195872A1 (en) Glp-1 prodrugs and uses hereof
CN118632867A (zh) Glp-1/gip受体共激动剂前药及其用途
EA049130B1 (ru) Коагонисты рецепторов glp-1 и gip, подходящие для пероральной доставки

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231114

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240207

R150 Certificate of patent or registration of utility model

Ref document number: 7434616

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150